Shares in Novo Nordisk and Eli Lilly have been under pressure after a study emerged suggesting that people taking a GLP-1 agonist had an elevated risk of a rare but serious eye condition.
Novo Nordisk has gone up another gear in its drive to boost manufacturing capacity for its fast-growing GLP-1 agonist drugs, announcing plans to build a $4.1 billion fill-and-finish facilit
Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabete
Scotland has become the first country in the UK to back NHS use of Eli Lilly’s obesity therapy Mounjaro, clearing it to assist weight management in eligible patients.
A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s
New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh